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A b s t r a c t
Background: Coronary revascularisation is common in heart failure (HF).
Aim: Clinical characteristic and assessment of in-hospital and long-term outcomes in patients hospitalised for HF with or 
without a previous percutaneous coronary intervention (PCI) or a coronary artery bypass grafting (CABG).
Methods: The primary endpoint (PE) (all-cause death) and the secondary endpoint (SE) (all-cause death or hospitalisation 
for HF-worsening) were assessed at one year in 649 inpatients of the ESC-HF Pilot Survey. Additionally, occurrence of death 
during index hospitalisation was evaluated.
Results: PCI/CABG-patients (32.7%) were more frequently male, smokers, and had myocardial infarction, hypertension, pe-
ripheral artery disease, and diabetes. The non-PCI/CABG-patients more often had cardiogenic shock and died in-hospital. The 
PE occurred in 33 of the 212 PCI/CABG-patients (15.6%) and in 56 of the 437 non-PCI/CABG-patients (12.8%; p = 0.3). The 
SE occurred in 82 of the 170 PCI/CABG-patients (48.2%) and in 122 of the 346 non-PCI/CABG-patients (35.3%; p = 0.01). 
Independent predictors of the PE in the PCI/CABG-patients were: lower left ventricular ejection fraction and use of anti-
platelets; in the non-PCI/CABG-patients were: age and acute coronary syndrome at admission. Independent predictors of SE 
in the PCI/CABG-patients were: diabetes, New York Heart Association (NYHA) class at admission, and hypertension; in the 
non-PCI/CABG-patients they were: NYHA class and haemoglobin at admission. Serum sodium concentration at admission was 
a predictor of PE and SE in both groups. Heart rate at discharge was a predictor of PE and SE in the non-PCI/CABG patients.
Conclusions: The revascularised HF patients had a similar mortality and higher risk of death or hospitalisation at 12 months 
compared with the non-PCI/CABG-patients. The revascularised patients had more comorbidities, while the non-PCI/CABG-pa-
tients had a higher incidence of cardiogenic shock and in-hospital mortality.
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INTRODUCTION
Heart failure (HF) is an increasingly common disease [1]. The 
chronic nature of HF is associated with poor outcomes, high 
healthcare costs, as well as being a leading cause of hospi-
talisation [1, 2]. Among the various causes of HF, ischaemic 
aetiology represents the majority, with incidence ranging 
between 30% and 57% [1–6]. This is firstly related to ageing 
modern societies developing left ventricular (LV) dysfunction 
as a manifestation of chronic coronary artery disease (CAD) 
[1–5], and secondly to improved survival of patients after 
acute myocardial infarction (MI) [1, 7]. 
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Coronary artery disease is a major contributor to mortal-
ity and morbidity in HF patients [6–8]. Over the last decade 
survival has significantly improved in HF patients who have 
undergone coronary revascularisation [7, 9]. Appropriate 
coronary revascularisation leads to improvement in quality 
of life in terms of freedom from angina, reduced angina 
frequency, improved measures of physical limitation, and 
treatment satisfaction in patients with MI and also in a stable 
CAD compared with only pharmacological therapy [7, 10, 11]. 
According to the AMI-PL database, about 80% of patients ad-
mitted with MI proceed with coronary revascularisation [12]. 
Improvement in CAD treatment with coronary artery by-pass 
grafting (CABG) or percutaneous coronary intervention (PCI) 
reduces in-hospital mortality but leads to an increased number 
of survivors with LV dysfunction [7, 10, 13]. Admission rates 
following HF hospitalisation remain high, especially after PCI, 
and pose a major economic problem for healthcare systems 
and patients themselves [1, 10]. In the AMI-PL database, in 
patients after MI, HF was the second most frequent cause of 
readmission during a one-year observation, (the first cause 
was stable CAD) [12].
In the AHEAD registry, approximately 30% of HF pa-
tients had a previous PCI or CABG [14], leaving a substantial 
group of patients for further investigation. Insight into clinical 
characteristics and factors related to worse prognosis may be 
a helpful component of comprehensive care of HF patients 
after coronary revascularisation. 
The objective of the present study was to evaluate clinical 
characteristics, as well as in-hospital and long-term outcomes 
of patients hospitalised for HF with or without previous PCI 




The Polish part of the ESC-HF Pilot Survey registry was 
a multicentre, prospective observational study conducted 
in 29 centres from Poland [15]. The survey enrolled adults 
(i.e. over 18 years old) with HF seen in ambulatory care, as 
well as inpatients admitted for acute or chronic HF during 
one particular day per week from October 2009 to May 
2010. Patients were followed for one year. 
Data collected in the registry relates to baseline charac-
teristics, clinical presentation, previous and current treatment, 
diagnostic tests results, clinical course of index hospitalisation 
(in the case of inpatients), and one-year follow-up. The Local 
Ethical Review Board approved the registry. All participating 
subjects were provided with detailed information, and all of 
them signed written consent. 
The current study included Polish patients of the ESC-HF 
Pilot Registry, who were hospitalised for HF (new onset or 
worsening). The study excluded outpatients seen in outpa-
tient care. 
Study groups — comparative analysis
Patients were divided into two groups with regard to occur-
rence of coronary revascularisation. Patients with PCI or CABG 
before admission were named as “PCI/CABG”. Patients with 
revascularisation during enrolment hospitalisation were not 
included into this group. In contrast, patients without previous 
revascularisation were named as “non-PCI/CABG”. 
We conducted a comparative analysis of the two 
groups. It included baseline characteristics, clinical status at 
hospital admission and at hospital discharge, in-hospital man-
agement of the patients, and pharmacotherapy. Patients were 
also compared with regard to in-hospital and one-year out-
comes. Predictors of the one-year outcomes were evaluated.
Study endpoints
The primary endpoint was all-cause death at 12 months after 
hospital discharge. The secondary endpoint was a composite 
of all-cause death and hospital readmissions for HF worsening 
at 12 months’ observation. Additionally, occurrence of death 
during index hospitalisation was evaluated.
Statistical analysis
All statistical analyses were performed using SAS software, 
version 9.2. (SAS Institute, United States). Normally distrib-
uted continuous variables were reported as mean and stand-
ard deviation. Ordinal variables and non-normally distributed 
continuous variables were shown as median (interquartile 
range [IQR]). All parameters in baseline characteristics were 
compared using Fisher’s exact test for categorical variables 
and the Mann-Whitney U test for continuous and ordinal 
variables. Cox proportional hazards regression analysis was 
performed to determine the risk factors of the primary and 
the secondary endpoints. In order to maintain adequate 
events per predictor variable value, due to the relatively 
small size of the study groups, variables with data missing 
for more than 5% were excluded from the Cox proportional 
hazards regression analyses [16]. Kaplan-Meier curves for 
both groups were delineated to show the primary and the 
secondary endpoints. Statistical significance was considered 
for p values < 0.05 for all tests. All factors that were found 
to be statistically significant in univariate analyses were in-




Figure 1 shows the flow chart of patient enrolment in the 
study. A total of 5118 patients were enrolled in the ESC-HF 
Pilot across Europe. In the Polish cohort of the registry, there 
were 893 participants, including 650 inpatients. For the 
final analysis, there were 649 patients hospitalised for HF 
(one patient with missing data on prior revascularisation 
was excluded). 
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Study group characteristics 
The history of prior PCI/CABG had 212 of the 649 patients 
(32.7%). Patients’ demographics, medical history, clinical 
course of index hospitalisation, management and diagnostic 
tests performed during hospitalisation, as well as in-hospital 
and one-year outcomes, are summarised in Tables 1–3. 
Primary endpoint
Data on one-year survival were available for the entire study 
group (649 patients). The primary endpoint occurred in 89 of 
the 649 patients (13.7%), including 33 of the 212 PCI/CABG 
group (15.6%) and in 56 of the 437 non-PCI/CABG group 
(12.8%; p = 0.3), as shown in Table 3. Kaplan-Meier curves 
for the primary endpoint in both groups are plotted in Fig-
ure 2. Univariate analyses of the prognostic factors of the pri-
mary endpoint are presented in the supplementary material, 
respectively, for the PCI/CABG group in Table S1 (see journal 
website) and for the non-PCI/CABG group in Table S2 (see 
journal website). All variables shown to be predictive of the 
primary endpoint in univariate analyses were consequently 
included in multivariate models, as presented in Table 4.
Secondary endpoint
The data on hospital readmission at 12 months were avail-
able for 516 patients (79.5% of 649 patients). The second-
ary endpoint occurred in 82 of the 170 PCI/CABG patients 
(48.2%) and in 122 of the 346 non-PCI/CABG patients (35.3%; 
p = 0.01), as shown in Table 3. Kaplan-Meier curves for the 
secondary endpoint in both groups are plotted in Figure 3. All 
variables predictive of the secondary endpoint in univariate 
analyses were consequently included in multivariate models, 
as presented in Table 4.
One-year outcomes in patients with CAD  
with or without previous PCI or CABG
Additionally, we performed also a sub-analysis including only 
patients with CAD. Data on one-year survival were avail-
able for the entire population with CAD (393 patients). The 
primary endpoint occurred in 63 of the 393 patients (16%), 
including 29 of the 199 PCI/CABG group (14.6%) and 34 of 
the 194 non-PCI/CABG group (17.5%; p = 0.5), The data 
on hospital readmission at 12 months were available for 
328 patients (83.5% of 393 patients). The secondary end-
point occurred in 137 of the 328 patients (41.8%), including 
77 of the 159 PCI/CABG patients (48.4%) and 60 of the 
169 non-PCI/CABG patients (35.5%; p = 0.02).
DISCUSSION
The HF Pilot Survey of the European Society of Cardiology 
(ESC) was a multicentre registry of HF patients across Europe 
[15]. In our previous publication of results of the ESC-HF 
Pilot registry on Polish hospitalised patients we showed that 
a history of previous PCI or CABG was an independent risk 
factor of combined endpoint of death or hospitalisation [17]. 
Coronary revascularisation is one of the key management 
considerations in patients with HF, besides pharmacological 
treatment and electrophysiological implantable devices [7]. 
In this study, we compared the clinical characteristics and 
5118 patients in Heart Failure Pilot Survey
893 patients enrolled in Polish centres
243 outpatients
650 patients hospitalised for heart failure
1 patient with missing data 
on prior revascularisation
649 patients included in the primary 
endpoint analysis
133 patients with missing data 
on rehospitalisation
516 patients included 
in the secondary endpoint analysis
Figure 1. Flow chart of patient enrolment in the current analysis
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prognostic factors in patients with and without previous re-
vascularisation. We also performed a sub-analysis aiming to 
compare one-year outcomes of HF patients with confirmed 
CAD with or without previous coronary revascularisation. Our 
objective was not to determine differences in survival based 
upon the revascularisation strategy (CABG or PCI).
The prevalence of an ischaemic aetiology of HF in our 
study is higher (60.6%) than in other registries (ADHERE 
— 57%, ATTEND — 33%, EHFS-II — 30%, OPTIMIZE-HF 
— 46%) [3–6]. In our analysis 33% of HF patients had prior 
PCI or CABG in their medical history, while in AHEAD reg-
istry 29.5% of HF patients had previously performed PCI or 
CABG [14]. 
The high proportion of males and CAD in the PCI/CABG 
group increased the frequency of other comorbidities [18]. 
Present analysis demonstrated that the PCI/CABG patients 
Table 1. Baseline clinical characteristics and previous pharmacotherapy in patients with or without previous coronary revascularisation
Variable Data on previous revascularisation (n = 649) p
PCI/CABG (n = 212) Non-PCI/CABG (n = 437)
Demographics
Age [years] 68 (58–76); n = 212 70 (58–78); n = 437 0.3
Male 75.0%; 159/212 59.3%; 259/437 < 0.0001
Body mass index [kg/m2] 27.7 (24.7–31.2); n = 190 27.7 (24.6–31.2); n = 381 1.0
Heart failure
LVEF [%] 32 (25–42); n = 179 39 (29–50); n = 388 < 0.0001
Ischaemic aetiology 93.9%; 199/212 44.4%; 194/437 < 0.0001
Hypertensive aetiology 0.5%; 1/212 15.6%; 68/437 < 0.0001
Valvular aetiology 3.3%; 7/212 15.6%; 68/437 < 0.0001
HFrEF 86.0%; 154/179 69.9%; 271/388 < 0.0001
Previous HF hospitalisation 64.6%; 137/212 54.0%; 237/437 0.01
Medical history
Hypertension 72.6%; 154/212 62.7%; 274/437 0.01
Myocardial infarction 94.8%; 201/212 41.4%; 181/437 < 0.0001
Peripheral artery disease 15.6%; 33/212 5.5%; 24/437 < 0.0001
Atrial fibrillation 37.7%; 80/212 39.6%; 172/434 0.7
Diabetes 43.9%; 93/212 31.4%; 137/437 0.002
Chronic kidney disease 25.5%; 54/212 21.7%; 95/437 0.3
COPD 11.3%; 24/212 13.3%; 58/436 0.5
Stroke 12.3%; 26/212 9.2%; 40/436 0.3
Current smoking 63.6%; 129/203 54.2%; 228/421 0.03
Previous pharmacotherapy
Diuretics 72.6%; 148/204 57.1%; 234/410 < 0.0001
Aldosterone antagonist 51.2%; 104/203 37.1%; 151/407 < 0.0001
ACEI 74.9%; 152/203 55.5%; 226/407 < 0.0001
ARB 5.9%; 12/203 8.9%; 36/404 0.3
Beta-blocker 84.7%; 172/203 65.6%; 267/407 < 0.0001
Statin 79.9%; 163/204 39.4%; 160/406 < 0.0001
Anticoagulants 26.3%; 54/205 27.6%; 112/406 0.8
Antiplatelets 76.1%; 156/205 41.9%; 168/405 < 0.0001
In each bar the total number (n) of patients for whom a given variable was available in the registry is shown. Continuous and ordinal variables are 
shown as a median/mean value and interquartile range/standard deviation. A p value of < 0.05 is considered statistically significant. Conversion 
factors to SI units are as follows: creatinine — 88.4, haemoglobin — 0.6206; ACEI — angiotensin-converting-enzyme inhibitor; ARB — angiotensin 
receptor blocker; CABG — coronary artery bypass grafting; COPD — chronic obstructive pulmonary disease; HF — heart failure; HFrEF — heart 
failure with reduced ejection fraction; LVEF — left ventricular ejection fraction; PCI — percutaneous coronary intervention
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Table 2. Clinical and laboratory status at hospital admission for patients with or without previous coronary revascularisation
Variable Data on previous revascularisation (n = 649) p
PCI/CABG (n = 212) Non-PCI/CABG (n = 437)
Clinical status at admission
Cardiogenic shock 0.5%; 1/186 3.7%; 15/404 0.03
NYHA class 3 (2–3); n = 210 3 (2–4); n = 435 0.2
SBP [mm Hg] 130 (110–147); n = 211 130 (120–150); n = 435 0.05
Heart rate [bmp] 80 (70–92); n = 210 80 (70–100); n = 436 0.003
VF or VT as a cause of admission 6.6%; 14/212 3.7%; 16/434 0.1
ACS as a cause of admission 34.9%; 74/212 27.1%; 118/435 0.04
AF as a cause of admission 11.4%; 24/211 16.8%; 71/424 0.08
Laboratory findings at admission
Serum sodium [mmol/L] 138 (136–141); n = 211 138.8 (136–141); n = 429 1.0
Serum potassium [mmol/L] 4.4 (4.1–4.7); n = 210 4.4 (4–4.8); n = 429 0.7
Serum creatinine [mg/dL] 1.10 (0.93–1.40); n = 206 1.09 (0.90–1.40); n = 412 0.2
Haemoglobin [g/dL] 13.2 (12.1–14.7); n = 208 13.3 (12.0–14.4); n = 426 0.6
In each bar the total number (n) of patients for whom a given variable was available in the registry is shown. Continuous and ordinal variables are 
shown as a median/mean value and interquartile range/standard deviation. A P value of < 0.05 is considered statistically significant. Conversion 
factors to SI units are as follows: creatinine — 88.4, haemoglobin — 0.6206; ACS — acute coronary syndrome; AF — atrial fibrillation; CABG — 
coronary artery bypass grafting; NYHA — New York Heart Association; PCI — percutaneous coronary intervention; SBP — systolic blood pressure; 
VF — ventricular fibrillation; VT — ventricular tachycardia
Table 3. Management during index hospitalisation, clinical status, and pharmacotherapy at discharge, as well as in-hospital and 
one-year outcomes of patients with or without previous coronary revascularisation
Variable Data on previous revascularisation (n = 649) p
PCI/CABG (n = 212) Non-PCI/CABG (n = 437)
Major management during index hospitalisation, clinical status at discharge
PCI/CABG during hospitalisation 28.0%; 44/212 9.6%; 42/437 < 0.0001
ICD implantation during hospitalisation 12.3%; 26/212 2.8%; 12/437 < 0.0001
Heart rate [bpm] 72 (65–80); n = 204 75 (68–87); n = 418 0.01
SBP [mm Hg] 120 (110–130); n = 208 120 (110–130); n = 419 0.5
Pharmacotherapy at hospital discharge*
Diuretics 86.7%; 182/210 84.7%; 355/419 0.2
Aldosterone antagonist 68.0%; 143/210 64.6%; 271/419 0.3
ACEI 77.1%; 162/210 76.1%; 319/419 0.4
ARB 9.0%; 19/210 8.7%; 36/413 0.8
Beta-blocker 93.3%; 196/210 84.7%; 355/419 0.01
Statin 84.8%; 178/210 64.4%; 270/419 < 0.0001
Anticoagulants 37.6%; 79/210 41.7%; 175/419 0.6
Antiplatelets 86.2%; 181/210 63.0%; 264/419 < 0.0001
In-hospital outcome
Hospitalisation length [days] 7 (4–11); n = 212 7 (4–11); n = 437 0.4
Death during hospitalisation 0.9%; 2/212 4.1%; 18/437 0.03
One-year outcome
Death 15.6%; 33/212 12.8%; 56/437 0.3
Death or hospitalisation 48.2%; 82/170 35.3%; 122/346 0.01
*In patients who survived to hospital discharge. In each bar the total number (n) of patients for whom a given variable was available in the  
registry is shown. Continuous and ordinal variables are shown as a median/mean value and interquartile range/standard deviation. A p value  
of < 0.05 is considered statistically significant. Conversion factors to SI units are as follows: creatinine — 88.4, haemoglobin — 0.6206; ACEI —  
angiotensin-converting-enzyme inhibitor; ARB — angiotensin receptor blocker; CABG — coronary artery bypass grafting; ICD — implantable 
cardioverter defibrillator; PCI — percutaneous coronary intervention; SBP — systolic blood pressure
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Figure 2. Kaplan-Meier curves for the primary endpoint in the 
PCI/CABG group and the non-PCI/CABG group; CABG —  
coronary artery bypass grafting; PCI — percutaneous coronary 
intervention
Figure 3. Kaplan-Meier curves for the secondary endpoint  
in the PCI/CABG group and the non-PCI/CABG group; CABG — 
coronary artery bypass grafting; PCI — percutaneous coronary 
intervention
Table 4. Multivariate analyses of the primary and the secondary endpoint in the PCI/CABG group and in the non-PCI/CABG group
Primary endpoint Secondary endpoint
HR (95% CI) p HR (95% CI) p
PCI/CABG group
History of hypertension – – 0.36 (0.22–0.61) 0.0001
History of diabetes – – 1.83 (1.15–2.93) 0.01
History of AF 1.80 (0.68–4.80) 0.2 1.53 (0.89–2.63) 0.1
Left ventricular ejection fraction [%] 0.95 (0.91–0.996) 0.03 – –
NYHA class at admission, per 1 class 1.45 (0.72–2.90) 0.3 1.50 (1.06–2.12) 0.02
SBP at admission, per 10 mm Hg 0.99 (0.97–1.00) 0.1 – –
Heart rate at admission, per 10 bpm 1.02 (0.998–1.03) 0.1 – –
AF as a cause of admission 2.57 (0.71–9.34) 0.2 1.76 (0.88–3.53) 0.1
Serum sodium at admission, per 0.5 mmol/L 0.85 (0.76–0.95) 0.01 0.91 (0.85–0.97) 0.002
Serum potassium at admission, per 1 mmol/L 1.07 (0.51–2.27) 0.9 – –
Serum creatinine at admission, per 1 mg/dL 1.65 (0.91–2.99) 0.1 1.16 (0.83–1.64) 0.4
ACEI treatment at discharge – – 0.75 (0.44–1.28) 0.3
Antiplatelet treatment at discharge 0.31 (0.11–0.86) 0.02 – –
Anticoagulant treatment at discharge – – 1.12 (0.66–1.88) 0.7
Non-PCI/CABG group
Age, per 10 years 1.05 (1.02–1.08) 0.001 – –
History of myocardial infarction 1.20 (0.66–2.17) 0.5 – –
History of diabetes 1.78 (0.99–3.20) 0.05 – –
NYHA class at admission, per 1 class 1.37 (0.89–2.09) 0.2 1.43 (1.09–1.88) 0.01
SBP at admission, per 10 mm Hg 0.997 (0.99–1.01) 0.6 0.99 (0.99–1.00) 0.09
Heart rate at admission, per 10 bpm 1.00 (0.99–1.02) 0.6 – –
Serum sodium at admission, per 0.5 mmol/L 0.89 (0.85–0.93) < 0.0001 0.95 (0.91–0.99) 0.02
Haemoglobin at admission, per 1 g/dL increase 0.92 (0.79–1.07) 0.3 0.87 (0.79–0.96) 0.01
ACS as a cause of admission 2.07 (1.16–3.69) 0.01 – –
Heart rate at discharge, per 10 bpm 1.03 (1.01–1.05) 0.0004 1.01 (1.00–1.02) 0.03
Beta-blocker treatment at discharge 0.66 (0.33–1.31) 0.2 – –
ACEI — angiotensin-converting-enzyme inhibitor; ACS — acute coronary syndrome; AF — atrial fibrillation; CABG — coronary artery bypass  
grafting; CI — confidence interval; HR — hazard ratio; NYHA — New York Heart Association; PCI — percutaneous coronary intervention;  
SBP — systolic blood pressure
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were more likely to have several risk factors and pre-existing 
diseases at baseline, including a history of MI, hypertension, 
peripheral artery disease, diabetes, and were more likely to 
smoke tobacco. Worse clinical condition potentially caused 
a higher rate of previous HF hospitalisations in those pa-
tients. As expected, due to a higher prevalence of CAD, the 
PCI/CABG patients more frequently had been prescribed an-
tiplatelets, statins, and beta-blockers at the time of discharge. 
Patients with prior coronary revascularisation had a lower 
left ventricular ejection fraction (LVEF), which could potentially 
explain the higher implantation rate of a cardioverter-defibril-
lator during hospitalisation. It also explains why those patients 
were more often treated with angiotensin converting enzyme 
inhibitors, aldosterone antagonists, and diuretics at the time 
of admission.
In comparison, the non-PCI/CABG group was character-
ised by a worse clinical status at hospital admission, which 
was manifested by a higher incidence of cardiogenic shock 
and higher in-hospital mortality. In the AMIS Plus Registry, 
investigators showed that increased rates of the PCI were 
associated with a decreased risk for development of cardio-
genic shock [19].
One-year outcomes 
Improved long-term prognosis in HF patients after coronary 
revascularisation was documented [10]. Favourable effects of 
coronary revascularisation are manifested by improvement in 
LVEF, New York Heart Association (NYHA) functional class, 
and protection against LV remodelling [20]. 
In our study, based on a real-life cohort of patients with 
HF, we observed similar mortality in one-year observation 
of HF patients with the prior revascularisation, compared to 
those without previous PCI or CABG. However, patients with 
documented revascularisation were at higher risk for death or 
hospitalisation (due to HF worsening) than the non-PCI/CABG 
patients. As with our study, in the EVEREST trial there was an 
observed increased risk of hospitalisations without associated 
increased risk of death [18]. The authors of the EVEREST trial 
evaluated the prognosis of HF patients with CAD, but they 
classified patients as having CAD based on the history of MI 
or coronary revascularisation [18]. 
Higher risk of hospitalisation likely depends on the overall 
disease burden. In the OPTIMIZE-HF registry, in a short-term 
observation (60 to 90 days) the mortality rate did not increase 
in patients with CAD, who underwent coronary revascularisa-
tion, compared to thosewithout CAD [6]. These data confirm 
that coronary revascularisation improves survival, but leaves 
a group of patients with impaired LV function and therefore 
with increased risk of HF worsening. 
The STICH trial evaluated effectiveness of a phar-
macotherapy alone versus the CABG in HF patients with 
LVEF < 35% and CAD [21]. In contrast to our study, the 
authors of the STICH trial excluded patients who were can-
didates for PCI. The investigators suggested that patients with 
poor exercise capacity have an increased risk of early death 
and similar five-year mortality after the CABG, compared to 
the pharmacotherapy alone. Whereas those with better exer-
cise capacity have an improved survival after the CABG [21]. 
These results suggest that it is necessary to identify patients for 
whom revascularisation might be more beneficial.
Mortality from CAD has been reduced due to the effective 
reperfusion strategies in acute MI. However, this has led to 
an increase in the incidence of HF with reduced LVEF, which 
is referred to as ischaemic cardiomyopathy [13]. According 
to the ESC guidelines, approximately half of patients with 
HF have reduced LVEF, which is regarded as an independent 
risk factor for poor outcomes [8]. In our study, lower LVEF 
was an independent predictor of mortality in the PCI/CABG 
patients. It could be suspected that use of antiplatelets at 
hospital discharge had a protective value for the primary 
endpoint in those patients. 
Interestingly, in our study hypertension had a protective 
value in the PCI/CABG patients. This result is also in line 
with the increased in-hospital mortality and frequent car-
diogenic shock occurrence observed in the non-PCI/CABG 
patients. These results suggest that a higher blood pressure in 
HF patients may be advantageous in the long-term observa-
tion and speak against excessive antihypertensive therapy in 
HF patients.
Diabetes mellitus is one of the major risk factors for CAD 
and often leads to the need for coronary revascularisation. 
Moreover, compared to the non-PCI/CABG patients, diabetes 
was an independent risk factor of the secondary endpoint in 
the PCI/CABG group. This is the same as in the OPTIMIZE-HF 
study [6]. This may suggest that there is a need for intensive 
blood glucose control and intensive antidiabetic treatment 
after coronary revascularisation. However, in the ACCORD 
study, which recruited patients with type 2 diabetes mellitus 
and other cardiovascular risk factors, the intensive hypogly-
caemic treatment with the goal of achieving normal HbA1c 
concentration was associated with an increase in mortality 
without significantly affecting the incidence of cardiovascu-
lar complications [22]. In our study, 30% of patients in the 
PCI/CABG group still required further revascularisation during 
index hospitalisation.
Due to the less frequent incidence of ischaemic HF in 
the non-PCI/CABG patients, attention should be paid towards 
other risk factors for unfavourable outcomes in this group. 
Anaemia in the HF population is associated with higher risk of 
death and hospitalisation [8]. Our study confirmed that lower 
haemoglobin concentration is an independent predictor of 
the secondary endpoint in the non-PCI/CABG patients. Also, 
a higher heart rate at discharge has previously been associ-
ated with greater mortality in HF patients [23]. In our study, 
this variable was found to be a significant risk factor of the 
primary and the secondary endpoint in the non-PCI/CABG 
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patients. This finding adds to the discussion about appropriate 
heart rate control in HF patients.  
According to the ATTEND registry, patients aged ≥ 65 years, 
compared to patients aged < 65 years, are characterised by 
higher short- and long-term mortality after hospital discharge 
and they are at increased risk for hospital readmissions [24]. 
In our study, older age was associated with unfavourable out-
comes in the non-PCI/CABG group, but not in patients with 
a previous history of PCI or CABG. The second predictor of the 
secondary endpoint in the non-PCI/CABG patients was acute 
coronary syndrome as a cause of admission. This may suggest 
a beneficial impact of previous revascularisation on prognosis 
of patients hospitalised with acute coronary syndrome.
In our previous study, we demonstrated that a higher 
NYHA functional class and hyponatraemia at hospital admis-
sion are significant predictors of one-year mortality in HF 
patients [17, 25]. In the present study, in both the PCI/CABG 
group and the non-PCI/CABG group, a NYHA functional class 
and hyponatraemia were independent predictors of the study 
endpoints. A higher NYHA functional class is closely related to 
advanced structural heart disease, manifested by severe symp-
toms of HF at rest or upon minimal exercise, despite intensive 
treatment being introduced [7, 8], whereas hyponatraemia is 
mostly caused by increased secretion of arginine vasopressin 
due to a low cardiac output and it is frequently aggravated 
by loop diuretics [25]. 
Our findings show that HF patients with previous 
coronary revascularisation remain at higher risk of death and 
hospitalisation, which also reflects their burden of numerous 
comorbidities. It shows that there is a need for targeted strate-
gies to improve patient care, mainly in ambulatory care, to 
reduce the rate of readmissions. Those components may have 
a significant impact on quality of life and costs of healthcare. 
It is also in-line with recommendations of investigators of the 
AMI-PL database, which suggest that cardiac rehabilitation and 
education in a field of self-management provided in patients 
after MI significantly reduced the number of readmissions [12].
Limitations of the study
The limitations of the study are a consequence of the ana-
lysed data. Registries have some drawbacks, such as their 
observational character and incompleteness of data. In the 
present study, data on hospitalisation at one year was missing 
for 133 out of the 649 patients, leaving 516 (80%) patients 
for the secondary endpoint analysis. However, there was no 
difference in the percentage of patients with missing data on 
hospitalisation between the analysed groups. Another limi-
tation of the study is that a collection of information about 
previous coronary revascularisation in the registry was not 
the main objective of the study. This resulted in a lack of ad-
ditional information about the severity of underlying CAD, the 
reason for not performing revascularisation in patients with 
known CAD, and the time from revascularisation to hospital 
admission. The type of revascularisation procedure (CABG or 
PCI) was also not analysed in this study. Our analysis aimed 
to characterise the whole population of HF patients who 
underwent previous coronary intervention (PCI or CABG) in 
comparison to those without previous revascularisation. The 
limited number of patients did not allow matching of both 
populations based on clinically relevant variables (i.e. ejection 
fraction, patients with already implanted ICD). Moreover, 
a longer duration of follow-up might be necessary to compare 
prognoses between study groups. Furthermore, it seems that 
performing a subanalysis of those patients’ outcomes regarding 
ejection fraction might provide important findings. 
CONCLUSIONS
In this analysis we characterised HF patients with prior PCI 
or CABG in comparison to the non-PCI/CABG group. The 
PCI/CABG patients were more likely to have numerous co-
morbidities, while the non-PCI/CABG patients more often 
had cardiogenic shock and died in hospital. Our results show 
that the HF patients who underwent revascularisation had 
a similar mortality and higher risk of death or hospitalisation 
at one year compared with the non-PCI/CABG patients. In 
the non-PCI/CABG patients an ischaemic aetiology of HF was 
observed less frequently, while the independent risk factors 
of the study endpoints were age, anaemia, and higher heart 
rate at discharge.
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